Expert Interview
Digging in to the Phase 2b data presented at the AAC Conference for Merck's oral PCSK9 inhibitor, MK-0616, in patients with hypercholesterolemia
Ticker(s): MRKInstitution: Private practice
- Interventional Cardiologist at Apex Cardiology
- Treats over 1000 CHF has prescribed Verquvo Manages 100 patients with Paroxysmal supraventricular tachycardia (PSVT)
- treats 1200 patient for hypercholesterolemia
- familiar with the reported data of Merck's oral PCSK9 inhibitor, MK-0616, and the results from the Phase 2b trial
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
